SPIA
TCRR

Steward Partners Investment Advisory’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Steward Partners Investment Advisory’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$4.42K – 7501
2021
Q1 		$4.42K Buy
+200
New +$5.45K ﹤0.01% 3039

Other funds holding TCRR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Steward Partners Investment Advisory's TCRR Position: Q2 2021 in Review

Steward Partners Investment Advisory sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2021, closing a stake of 200 shares — an estimated $4.42K sold.

Steward Partners Investment Advisory first reported a position in TCRR in Q1 2021 and held it in 1 quarter. The position peaked at $4.42K in Q1 2021. 119 funds tracked by Wall St. Rank hold TCRR as of Q2 2021.

  • Steward Partners Investment Advisory reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 200 TCR2 Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $4.42K.
  • Steward Partners Investment Advisory first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Steward Partners Investment Advisory's TCR2 Therapeutics Inc. Common Stock position peaked at $4.42K in Q1 2021.
  • 119 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.